Search results for "FEV1"

showing 10 items of 132 documents

Effects of a structured educational intervention in moderate-to-severe elderly asthmatic subjects.

2019

Background: Adherence to inhaled drugs is linked to patients’ satisfaction with their device, and an incorrect use can negatively affect the outcomes of asthma treatment. We speculated that this is particularly true in elderly asthmatic subjects. Aim: We performed a national pre-post interventional multicentre study, enrolling moderate-to-severe asthmatic subjects aged ≥65 ​years treated with fixed inhaled combination drugs by dry powder inhaler (DPI) or pressurized metered dose inhaler (pMDI). Adherence and critical errors were evaluated by means of validated questionnaires at first visit (V1) and after 3–6 months (V2). At V1, subjects underwent intensive training on the correct use of the…

Vital capacityACT asthma control testExacerbationSAE severe asthma exacerbationSF12chlorofluorocarbonsmental health composite scoreEDUCA elderly and device use in chronic asthmaPCS physical health composite scoreACT asthma control test; AHDS hospital anxiety depression scale; Asthma; CFC chlorofluorocarbons; Device misuse; EDUCA elderly and device use in chronic asthma; Education; Elderly; FEV1 forced expiratory volume 1s second; FVC forced vital capacity; ICS inhaled corticosteroids; LABA long-acting β2 agonist; LAMA long-acting muscarinic antagonists; MCS mental health composite score; PCS physical health composite score; PROs patient-reported outcomes; SAE severe asthma exacerbation; SF12 short form health survey; mMRC modified medical research councilEDUCAFEV10302 clinical medicineElderlyImmunology and AllergyMedicine030223 otorhinolaryngologybiologymMRC modified medical research councilsevere asthma exacerbationmodified medical research councilLAMASAELamaelderly and device use in chronic asthmaMetered-dose inhalerDry-powder inhalerDevice misusePROs patient-reported outcomesCFCPCSpatient-reported outcomesmMRClcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinelong-acting β2 agonistmedicine.medical_specialtyImmunologyLABAphysical health composite scoreArticleLAMA long-acting muscarinic antagonistsAHDSEducation03 medical and health sciencesFEV1/FVC ratiolong-acting muscarinic antagonistsforced vital capacitySF12 short form health surveyAsthma; Device misuse; Education; ElderlyInternal medicineMCS mental health composite scoreforced expiratory volume 1s secondAsthmabusiness.industryFEV1 forced expiratory volume 1s secondInhalerasthma control testbiology.organism_classificationmedicine.diseaseCFC chlorofluorocarbonsACTICS inhaled corticosteroidsFVCAsthmaMCShospital anxiety depression scale030228 respiratory systemICSAHDS hospital anxiety depression scaleFVC forced vital capacityPROsshort form health surveyinhaled corticosteroidslcsh:RC581-607businessLABA long-acting β2 agonistThe World Allergy Organization journal
researchProduct

Causal Effects of Body Mass Index on Airflow Obstruction and Forced Mid-Expiratory Flow: A Mendelian Randomization Study Taking Interactions and Age-…

2021

Obesity has complex links to respiratory health. Mendelian randomization (MR) enables assessment of causality of body mass index (BMI) effects on airflow obstruction and mid-expiratory flow. In the adult SAPALDIA cohort, recruiting 9,651 population-representative samples aged 18–60 years at baseline (female 51%), BMI and the ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) as well as forced mid-expiratory flow (FEF25–75%) were measured three times over 20 follow-up years. The causal effects of BMI in childhood and adulthood on FEV1/FVC and FEF25–75% were assessed in predictive (BMI averaged over 1st and 2nd, lung function (LF) averaged over 2nd and 3rd fol…

Vital capacityPulmonary Disease Chronic Obstructive0302 clinical medicinePULMONARY-DISEASEMedicineLungPublic Environmental & Occupational HealthOriginal Research2. Zero hungerRISK0303 health sciencesCOPDInstrumental variableAge Factorslongitudinal cohortgenetic score3. Good healthOBESITYCohortLife course approachFemalePublic HealthPublic aspects of medicineRA1-1270Life Sciences & BiomedicineAdultbody mass index1117 Public Health and Health Services03 medical and health sciencesFEV1/FVC ratioMendelian randomizationLUNG-FUNCTION DECLINEMendelian randomizationQUALITYHumansCOPDGENOME-WIDE ASSOCIATION030304 developmental biologyScience & Technologybusiness.industryPublic Health Environmental and Occupational Healthnutritional and metabolic diseaseslung functionADULTSMendelian Randomization Analysismedicine.diseaseCross-Sectional Studies030228 respiratory systemASTHMAbusinessFOLLOW-UPBody mass indexDemographyFrontiers in Public Health
researchProduct

Relationship Between Patient-Reported Outcomes and Clinical Outcomes in Patients With Morquio A Syndrome

2019

Abstract This cross-sectional analysis assessed the correlation between patient-reported outcomes (PROs) and clinical outcomes in 24 German patients with Morquio A. Clinical outcomes included 6-minute walk test (6MWT), 3-minute stair climb (3MSC) test, and joint range of motion as measures for endurance/mobility, forced vital capacity (FVC) and maximum voluntary ventilation (MVV) as measures for respiratory function, and height as an important manifestation. The PROs included the EuroQoL (EQ) 5D-5L (EQ5D-5L), to measure health-related QoL (HRQoL), and patients’ rating of their ability to walk, climb, or breathe. In adults, endurance and pulmonary function measures and height showed strong a…

Vital capacitymedicine.medical_specialtyEndocrinology Diabetes and Metabolismmaximal voluntary ventilationPulmonary function testingFEV1/FVC ratioMaximal Voluntary VentilationPhysical medicine and rehabilitationQuality of lifepatient’s perceptionMorquio A6MWTmedicineRespiratory functionGenetics (clinical)lcsh:R5-920EQ5D-5Lbusiness.industryrespiratory function testsFVCmobilityhumanitiesTest (assessment)quality of lifepatient-reported outcomesPediatrics Perinatology and Child HealthPhysical therapyRange of motionbusiness3MSC testlcsh:Medicine (General)physical endurancehuman activitiesmucopolysaccharidosis IVJournal of Inborn Errors of Metabolism and Screening
researchProduct

Evaluation of the long-term treatment effects of idursulfase using statistical modelling: Data from the Hunter Outcome Survey (HOS)

2019

Treatment for mucopolysaccharidosis type II (MPS II Hunter syndrome) is available in the form of intravenous enzyme replacement therapy (ERT) with idursulfase (Shire, Lexington, MA, USA). This analysis used statistical modelling to evaluate the long-term treatment effects of idursulfase on selected clinical parameters based on data from HOS, a global, observational registry (Shire, Lexington, MA, USA). Mixed modelling was used to analyse data from male patients followed prospectively in HOS who had received idursulfase for 5-8 years and information available for two or more timepoints, of which one was pre-ERT. Data were excluded from patients with only pre-ERT information available, who ha…

Vital capacitymedicine.medical_specialtyIdursulfasebusiness.industryEndocrinology Diabetes and MetabolismHunter syndromeEnzyme replacement therapymedicine.diseaseBiochemistryClinical trialFEV1/FVC ratioEndocrinologyInternal medicineGeneticsmedicineObservational studyMucopolysaccharidosis type IIbusinessMolecular Biologymedicine.drugMolecular Genetics and Metabolism
researchProduct

Burden of Comorbidities in Patients with OSAS and COPD-OSAS Overlap Syndrome

2021

Background and Objectives: Obstructive sleep apnea syndrome (OSAS) and chronic obstructive pulmonary disease (COPD) are usually associated with multi-morbidity. The aim of this study was to retrospectively investigate the prevalence of comorbidities in a cohort of patients with OSAS and COPD-OSAS overlap syndrome (OS) patients and to explore differences between these two groups. Materials and Methods: Included were consecutive OS patients and OSAS patients who had been referred to our sleep laboratory, and were matched in terms of sex, age, BMI, and smoking history. Presence of comorbidities was recorded based on their medical history and after clinical and laboratory examination. Results: …

comorbiditiemedicine.medical_specialtyMedicine (General)obstructive sleep apnea syndromeComorbiditySettore MED/10 - Malattie Dell'Apparato Respiratoriooverlap syndromecomorbiditiesArticlechronic obstructive pulmonary diseaseFEV1/FVC ratioPulmonary Disease Chronic ObstructiveR5-920cardiovascular diseaseInternal medicinemedicineHumansRetrospective StudiesCOPDSleep Apnea Obstructivebusiness.industryOverlap syndromeGeneral Medicinemedicine.diseaseComorbiditynervous system diseasesRespiratory Function Testsrespiratory tract diseasesObstructive sleep apneaApnea–hypopnea indexCohortbusinessDyslipidemiaMedicina
researchProduct

Antisynthetase syndrome (AS) in patients with diffuse interstitial lung disease (ILD)

2015

Objectives: To determine the prevalence of SAS in patients with ILD and its clinical characteristics, evolution and specific manifestations linked to each antisynthetase antibodies and highlight the need for its screening in ILD. Methods: Retrospective analysis of patients registered in the last two years in our ILD unit, determining antisynthetase antibodies and analyzing clinical, radiological, functional data and illness evolution. Results: 119 ILD patients were included, 10.9% had antisynthetase antibodies, the most prevalent were Jo-1 (46.1%) and PL-12 (38.5%). In PL-12 patients inicial and respiratory syntoms were predominant, whereas in the Jo-1 patients were more frequent extrapulmo…

medicine.medical_specialtyPathologybusiness.industryInterstitial lung diseaseAntisynthetase syndromerespiratory systemmedicine.diseasebehavioral disciplines and activitiesResponse to treatmentrespiratory tract diseasesbody regionsFEV1/FVC ratioInternal medicinemedicineRetrospective analysisIn patientRespiratory systembusinessInterstitial Disease1.5 Diffuse Parenchymal Lung Disease
researchProduct

Objectifying acupuncture effects by lung function and numeric rating scale in patients undergoing heart surgery.

2012

Rationale. Poststernotomy pain and impaired breathing are common clinical problems in early postoperative care following heart surgery. Insufficiently treated pain increases the risk of pulmonary complications. High-dose opioids are used for pain management, but they may cause side effects such as respiratory depression.Study Design. We performed a prospective, randomized, controlled, observer-blinded, three-armed clinical trial with 100 patients. Group 1 (n=33) and Group 2 (n=34) received one 20 min session of standardized acupuncture treatment with two different sets of acupoints. Group 3 (n=33) served as standard analgesia control without additional intervention. Results. Primary endpoin…

medicine.medical_specialtyVital capacityArticle Subjectbusiness.industryAnalgesiclcsh:Other systems of medicinelcsh:RZ201-999Pulmonary function testingSurgeryClinical trialFEV1/FVC ratioComplementary and alternative medicineStatistical significanceAcupuncturemedicineClinical endpointbusinessResearch ArticleEvidence-based complementary and alternative medicine : eCAM
researchProduct

Abdominal wall incisional hernia repair improves respiratory function: results after 3 years of follow-up

2020

Abstract Purpose Hernias severely impact patient quality of life (QoL), and 80% of patients require a surgical operation. Moreover, hernias are responsible for respiratory function alterations. This study aims to investigate the postoperative alterations in respiratory function after open ventral hernia repair in patients with incisional hernia. Methods Patients operated on at the Policlinico “Paolo Giaccone” at Palermo University Hospital between January 2015 and December 2016 were identified in a prospective database. Fifty-one patients were enrolled in the study. The respiratory outcome measures used were forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FEV1/FVC ratio…

medicine.medical_specialtyVital capacityIncisional herniaVentral hernia repairAbdominal wallFEV1/FVC ratioQuality of lifemedicineHumansRespiratory functionRespiratory systemRespiratory outcomeIncisional herniaHerniorrhaphybusiness.industryAbdominal Wallrespiratory systemmedicine.diseaseHernia Ventralrespiratory tract diseasesSurgerymedicine.anatomical_structureQuality of LifeOriginal ArticleSurgerybusinesscirculatory and respiratory physiologyFollow-Up StudiesAbdominal surgery
researchProduct

Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.

2020

Background: The comparative efficacy of pirfenidone, nintedanib, and pamrevlumab in slowing the rate of forced vital capacity (FVC) decline and mortality in patients with idiopathic pulmonary fibrosis (IPF) is unknown. Objective: To perform a systematic review and meta-analysis (MA) of these drugs for IPF. Methods: We searched CENTRAL, PubMed, EMBASE, ClincalTrials.gov, and the World Health Organization’s registry databases up to March 2020. Phase II/III randomized controlled trials in adults with IPF were eligible. The random-effect model was implemented calculating the effect size and respective 95% CI as Cohen’s d for change from baseline FVC (in percentage predicted and liters) and odds…

medicine.medical_specialtyVital capacityIndolesPyridones03 medical and health scienceschemistry.chemical_compoundFEV1/FVC ratioIdiopathic pulmonary fibrosis0302 clinical medicineInternal medicinemedicineHumansPharmacology (medical)In patient030212 general & internal medicinebusiness.industryPirfenidonemedicine.diseaseIdiopathic Pulmonary FibrosisTreatment Outcome030228 respiratory systemchemistryMeta-analysisNintedanibbusinessAll cause mortalitymedicine.drugThe Annals of pharmacotherapy
researchProduct

SVC Is a Marker of Respiratory Decline Function, Similar to FVC, in Patients With ALS

2019

Copyright © 2019 Pinto and de Carvalho. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

medicine.medical_specialtyVital capacityPrognostic variableamyotrophic lateral sclerosisNeurologyNeurologipredictorlcsh:RC346-429functional outcome03 medical and health sciencesFEV1/FVC ratioslow vital capacity0302 clinical medicineInternal medicinemedicineRespiratory function030212 general & internal medicineAmyotrophic lateral sclerosisRespiratory systemlcsh:Neurology. Diseases of the nervous systembusiness.industryProportional hazards modelNeurosciencesBrief Research Reportmedicine.diseaseNeurologyCardiologyrate of progressionNeurology (clinical)business030217 neurology & neurosurgeryNeurovetenskaperFrontiers in Neurology
researchProduct